INTRODUCTION
============

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed for several conditions, including rheumatoid arthritis, osteoarthritis, and musculoskeletal injuries.[@b1-gnl-8-371] The administration of NSAIDs, however, can cause gastrointestinal complications, such as bleeding, ulceration, perforation, and obstruction. The factors that increase the risk of NSAID-induced gastrointestinal complications include age over 60 years, concomitant use of systemic corticosteroids, or anticoagulants, and a history of peptic ulcer.[@b2-gnl-8-371]--[@b6-gnl-8-371] NSAID-induced gastrointestinal complications are caused by various mechanisms, such as abnormalities in prostaglandin-dependent gastric mucosal protection caused by decreased gastric mucosal prostaglandins.[@b7-gnl-8-371]

Cyclooxygenase 2 (COX-2) inhibitors, which are known to be safer than other NSAIDs, are used to reduce NSAID-induced gastrointestinal side effects. Many doubts still exist, however, about the clinical safety of COX-2 inhibitors, as illustrated by the removal of the COX-2 inhibitor rofecoxib from the market.[@b8-gnl-8-371] Cotherapy with misoprostol or proton pump inhibitors (PPIs) is another way to prevent NSAID-induced gastrointestinal complications; however, misoprostol itself can cause side effects, such as abdominal pain, diarrhea, and dyspepsia, which can decrease medication compliance.[@b1-gnl-8-371] Long-term PPI administration is also problematic because issues such as osteoporosis, aspiration pneumonia, and atrophic gastritis may result.[@b9-gnl-8-371]

Rebamipide is an antiulcer drug that protects gastric epithelial cells, improves gastric defense mechanisms by increasing gastric mucus, increases prostaglandin production, and reduces free oxygen radicals.[@b10-gnl-8-371]--[@b13-gnl-8-371] In healthy volunteers, rebamipide is effective at preventing the gastric injury caused by the administration of indomethacin. Although the preventive effects of rebamipide on NSAID-induced gastropathy are equivalent to those of misoprostol, rebamipide has been reported to cause fewer side effects (e.g., lower incidences of diarrhea, lower abdominal pain, and abdominal distension).[@b14-gnl-8-371],[@b15-gnl-8-371] The present study evaluated the efficacy and safety of rebamipide for preventing gastrointestinal complications due to NSAIDs by comparing it with misoprostol in a randomized, multicenter, double-blind study of patients with a high risk of NSAIDs complications.

MATERIALS AND METHODS
=====================

1. Patients
-----------

The present study was conducted in patients who presented at the Yeouido St. Mary's Hospital of The Catholic University of Korea College of Medicine and 16 other hospitals from January 2008 to March 2010. The inclusion criteria were patients over the age of 19 years who had rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and other joint diseases that require continuous administration of NSAIDs for more than 12 weeks. Patients with a modified Lanza score below 3 in an upper gastrointestinal endoscopy who did not have current gastrointestinal symptoms and who had at least one of the following ulcer risk factors were selected for the study population: history of peptic ulcer identified through an upper gastrointestinal endoscopy, over the age of 60 years, and concomitant therapy with systemic corticosteroids (taking more than 5 mg/day of prednisolone or the equivalent dose of steroid).[@b16-gnl-8-371] The following exclusion criteria were used: patients with a history of gastrointestinal surgery (except appendectomy); patients with abnormal bleeding tendency (abnormalities in platelets or blood clotting factors); patients with active gastroduodenal ulcers, gastroesophageal reflux disease, gastroesophageal varices, Barrett's esophagus, esophageal strictures, or malignant tumors in an upper gastrointestinal endoscopy; patients diagnosed with malabsorption within the last 3 months; patients with a history of cerebrovascular disease, coronary artery disease, diabetes mellitus, pancreatitis, chronic kidney disease, chronic liver disease, or malignant tumors; patients who were using medications that affect gastrointestinal motility, such as sucralfate, H~2~-receptor antagonists, misoprostol, and prokinetics, within a week of participating in the study; patients who were using aspirin or anticoagulants; patients who were using a PPI within 2 weeks of participating in the study; pregnant or nursing women; and women of childbearing age who were not using a medically confirmed method of contraception.

Before the clinical trial was conducted, the protocols, informed consent forms, and all other related matters were approved by the Korea Food and Drug Administration and the Institutional Review Board of the corresponding institution that was conducting the clinical trial.

2. Methods
----------

This study was as a double-blind, double-dummy, randomized, multicenter, parallel comparison clinical trial. This study consisted of a screening period for 1 or 2 weeks before enrollment, treatment period for 12 weeks, and safety follow-up period for the 30 days after last investigational product (IP) administration ([Fig. 1](#f1-gnl-8-371){ref-type="fig"}). The subjects who agreed to participate and met the inclusion criteria were randomly assigned to either the treatment (rebamipide) or control (misoprostol) group. The treatment group received 100 mg of rebamipide three times a day, and the control group received 200 μg of misoprostol three times a day for 12 weeks. As for NSAIDs, after stopping NSAIDs taken currently for 1 to 2 weeks, one of medications in the following, which fits a subject, was administered for 12 weeks from the randomization day: 100 mg of aceclofenac twice a day, 15 mg of meloxicam once a day, or 1,000 mg of nabumetone once a day ([Table 1](#t1-gnl-8-371){ref-type="table"}). An upper gastrointestinal endoscopy was performed during screening and 12 weeks after the IP administration to evaluate the efficacy. To evaluate safety, vital signs and blood chemistry were assessed during every visit from screening period to the last day of IP administration. The subjects with major protocol deviation (e.g., less than 80% IP compliance and not taking NSAIDs for 5 consecutive days) were excluded from the per protocol (PP) analysis set.

Taking the following concomitant medications which can affect the clinical symptoms or efficacy evaluation was prohibited: anticholinergic drugs, H~2~-receptor antagonists, PPIs, sucralfate, prokinetics, antacids (except aluminum hydroxide gel, which was allowed as a rescue medication), prostaglandin drugs other than misoprostol, other drugs affecting gastric acid secretion and gastrointestinal motility, anticancer drugs, anticoagulants, and NSAIDs other than those provided by the sponsor.

The primary efficacy endpoint was the occurrence rate of gastric ulcer confirmed on gastrointestinal endoscopy that was performed 12 weeks after the IP administration. An ulcer was defined as an excavated mucosal layer with a diameter of greater than 3 mm. The occurrence rate of gastric ulcer was determined with the following equation: (the number of subjects with gastric ulcer/the total number of subjects in the analysis set)×100. The therapeutic failure rate, the severity of gastrointestinal symptoms, and the amount of antacid used were evaluated as secondary efficacy endpoints. Therapeutic failure was defined as developing a gastric ulcer or withdrawal due to intractable gastrointestinal symptoms, which might be major side effect of misoprostol.

The gastrointestinal symptoms consisted of seven items: heartburn, abdominal distention, nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. To compare the total severity score of gastrointestinal symptoms between the two groups, each item was evaluated as no symptoms (0 points), mild symptoms (1 point), moderate symptoms (2 points), or severe symptoms (3 points). The amount of antacid used (the total number of tablets taken) in the two groups during the clinical trial was compared.

3. Statistics
-------------

From the results of previous clinical studies of misoprostol (the control drug), the occurrence rate of gastric ulcer was assumed to be 3.7%. The clinically acceptable margin (δ) for noninferiority trial was assumed to be 6.9%[@b1-gnl-8-371],[@b17-gnl-8-371] because 6.9% is half of 13.8%, which is the difference between the occurrence rate of gastric ulcer of placebo (17.5%) and misoprostol (3.7%). Assuming a significance level (a) of 0.025 in a one-sided test, a statistical power (1-b) of 90%, and a 1:1 treatment to control group ratio, the number of subjects (n) required for each group was 158. Assuming a dropout rate of 20%, the total number of subjects was set to 396 (198 in each group).

The efficacy variables included the occurrence rate of gastric ulcer, the frequency and rate of the therapeutic failure. For the occurrence rate of gastric ulcer and the therapeutic failure rate, frequency and percentage of the occurrence of gastric ulcer and the therapeutic failure were obtained, and the comparison of their rate between groups were performed using chi-square test. A repeated measures analysis of variance was used to compare the severity of gastrointestinal symptoms between the two groups. A two-sample t-test or Wilcoxon rank sum test was used to compare amount of antacid consumption between the two groups.

For the percentage of the subjects who experienced adverse events (AEs) more than once, a 95% confidence interval was obtained and the difference between groups was compared using chi-square test or Fisher exact test. SAS version 9.1 (SAS Institute, Cary, NC, USA) was used to perform the statistical analysis.

RESULTS
=======

1. Patient population
---------------------

A total of 664 patients from 17 sites received a screening test. Among the 664 patients, 185 were excluded, and 479 were determined to meet the inclusion criteria. Of the 479 patients, 237 were randomly assigned to the control (misoprostol) group, and 242 were assigned to the treatment (rebamipide) group. Four hundred seventy-eight subjects received the IP at least once (one subject in the misoprostol group did not), and 410 subjects completed the clinical trial: 193 subjects in the misoprostol group and 217 subjects in the rebamipide group ([Fig. 2](#f2-gnl-8-371){ref-type="fig"}). Sixty-nine of the randomly assigned subjects withdrew from the trial: 44 subjects in the misoprostol group (18.6%) and 25 subjects in the rebamipide group (10.3%). The withdrawal rate was significantly greater in the misoprostol group compared with the rebamipide group (p=0.0103 in a chi-square test). The patients provided the following reasons for withdrawal: 14 subjects withdrew because of AE (10 in the misoprostol group and four in the rebamipide group), four subjects withdrew because of poor protocol compliance (one in the misoprostol group and three in the rebamipide group), and 48 subjects withdrew because of the withdrawal due to gastrointestinal pain (33 in the misoprostol group and 15 in the rebamipide group) ([Table 2](#t2-gnl-8-371){ref-type="table"}). Therefore, the major analysis set for the efficacy in this study is the intention to treat (ITT) analysis set because the PP analysis set is decided as less valid than ITT analysis set due to significant difference in the withdrawal rate in between the two groups. There were no significant differences between the groups regarding age, sex, smoking history, ulcer risk factors, or modified Lanza scores from the endoscopy. The prevalence of ankylosing spondylitis, however, was significantly greater in the misoprostol group (p=0.0358) ([Table 3](#t3-gnl-8-371){ref-type="table"}).

2. Treatment efficacy
---------------------

### 1) Primary efficacy endpoint

The primary efficacy endpoint was the occurrence rate of gastric ulcer from the upper gastrointestinal endoscopy (i.e., the percentage of subjects in each analysis set with a confirmed gastric ulcer). The subject who missed the gastrointestinal endoscopy evaluation in 12 weeks of IP administration due to the withdrawal was regarded as the subject with gastric ulcer (therapeutic failure) in the ITT analysis set. The occurrence rate of gastric ulcer did not significantly differ in the ITT analysis set: 21.9% (52/237 subjects) for the misoprostol group and 20.3% (49/242 subjects) for the rebamipide group (p=0.6497) ([Table 4](#t4-gnl-8-371){ref-type="table"}).

### 2) Secondary efficacy endpoints

The secondary efficacy endpoints were therapeutic failure rate, the severity of gastrointestinal symptoms, and the amount of antacid used. The therapeutic failure rates did not significantly differ between the two groups: 13.1% (31/237 subjects) for the misoprostol group and 13.6% (33/242 subjects) for the rebamipide group (p=0.8580) ([Table 5](#t5-gnl-8-371){ref-type="table"}).

The total severity score of gastrointestinal symptom in the misoprostol group were 0.33±0.59 before IP administration, 0.80±1.14 at 4 weeks, 0.67±1.19 at 8 weeks, and 0.67±1.24 at 12 weeks. The total severity scores in the rebamipide group were generally lower than those in the misoprostol group: 0.24±0.54 before IP administration, 0.44±0.92 at 4 weeks, 0.36±0.78 at 8 weeks, and 0.44±1.05 at 12 weeks. In the repeated measures analysis of variance, the severity of gastrointestinal symptoms was significantly lower in the rebamipide group compared with the misoprostol group (a significant group effect, p=0.0002) ([Table 6](#t6-gnl-8-371){ref-type="table"}).

In the ITT analysis, the number of antacid tablet was 11.18±22.79 for the misoprostol group and 7.19±15.49 for the rebamipide group (p=0.0258) ([Table 7](#t7-gnl-8-371){ref-type="table"}).

3. Safety evaluation
--------------------

The safety evaluation was conducted with the 478 subjects who were randomized and received IP at least once. One of subjects had excluded on the safety evaluation because the subject couldn't take an IP. All the AEs which occurred in this study were classified into nontreatment emergent adverse event (non-TEAE) occurring before administration of the IP and from the day corresponding to five times the half-life after the last administration day until 30 days (after the last administration day); and exacerbation of pre-existing symptoms or AEs which the subject experienced initially after IP administration (TEAE). During the clinical trial period, 805 AEs occurred in 331 of the 478 subjects (69.3%): 166 misoprostol subjects (70.3%, 400 events) and 165 rebamipide subjects (68.2%, 405 events). There were 720 TEAEs in 319 subjects (66.7%), and the incidence of these events did not significantly differ between the groups: 161 subjects for misoprostol (68.2%, 373 events) and 158 subjects for rebamipide (65.3%, 347 events). However, the majority of the rebamipide group's TEAEs were mild (misoprostol group, 76.1% \[284/373 events\]; rebamipide group, 85.0% \[295/347 events\]), and the proportion of moderate or severe TEAEs was higher in the misoprostol group (misoprostol group, 23.9% \[89/373 events\], rebamipide group, 15.0% \[52/347 events\]) ([Table 8](#t8-gnl-8-371){ref-type="table"}).

The most common adverse drug reaction (ADR) was gastrointestinal disorders: 64 subjects (27.1%) in the misoprostol group and 47 subjects (19.4%) in the rebamipide group; however, the difference was not statistically significant. Nausea was significantly more common in the misoprostol group (15 subjects, 6.4%) compared with the rebamipide group (four subjects, 1.7%) (p=0.0095) ([Table 9](#t9-gnl-8-371){ref-type="table"}).

DISCUSSION
==========

Approximately 10% to 60% of patients who take NSAIDs experience gastrointestinal symptoms (e.g., abdominal pain, heartburn, bloating, and indigestion). Interestingly, 10% to 20% of the rheumatoid arthritis patients who start NSAIDs discontinue them due to gastrointestinal symptoms.[@b18-gnl-8-371] Thus, preventing gastrointestinal symptoms (in addition to preventing peptic ulcers) is an important treatment goal in patients taking NSAIDs. It is difficult to obtain an accurate incidence for NSAID-induced ulcers because many cases are asymptomatic. In an upper gastrointestinal endoscopy study of patients taking NSAIDs, gastric ulcers occurred in 10% to 40% of the patients within the first 3 months of NSAID use, and duodenal ulcers were reported in 4% to 15% of the cases.[@b19-gnl-8-371]

A PP analysis is not regarded as a valid in the current study due to the significantly greater number of patients in the misoprostol group who withdrew compared with the rebamipide group. In a previous lansoprazole study, the ITT results were also used as the primary analysis because the PP analysis was not valid due to significant difference in the withdrawal rate in between the two groups.[@b19-gnl-8-371] In the ITT analysis of the current study, the occurrence rate of gastric ulcer in the misoprostol group (21.9%, 52/237 subjects) was not significantly different (p=0.6497) from the rate in the rebamipide group (20.3%, 49/242 subjects).

In a previous study about the efficacy of the PPI drug lansoprazole to prevent NSAID-induced gastric ulcers, the percentages of subjects without gastric ulcers after 12 weeks of medication were 51% for the placebo group, 93% for the misoprostol group (200 μg four times/day), 80% for the 15 mg lansoprazole group, and 82% for the 30 mg lansoprazole group. Although the lansoprazole groups had a significant (p\<0.001) gastric ulcer protective effect compared with the placebo group, the protective effect was significantly smaller (p=0.01 and p=0.04 for the 15 and 30 mg groups, respectively) than the effect of misoprostol. However, the misoprostol group had several early trial withdrawals due to AEs. When these withdrawals were regarded as therapeutic failures, the successful treatment percentages were 69% for the misoprostol group, the 15 mg lansoprazole group, and the 30 mg lansoprazole group and 35% for the placebo group.[@b19-gnl-8-371] Given the low medication compliance and high gastrointestinal-related AE rates for misoprostol, lansoprazole was judged to have high practical clinical value in patients using NSAIDs for extended periods; therefore, it was approved by the U.S. Food and Drug Administration in November 2011.

The misoprostol group may have more patients who withdrew early due to gastrointestinal pain because of gastrointestinal symptoms from incipient gastric ulcers. Furthermore, the time to the first AE in the patients who dropped out was 36 days for the misoprostol group and 56 days for the rebamipide group, and the more rapid onset of AEs in the misoprostol group may have affected the withdrawal rate ([Fig. 3](#f3-gnl-8-371){ref-type="fig"}). In addition to misoprostol, PPI cotherapy is used to prevent NSAID-induced gastrointestinal injury. According to recent data from Cochrane, the prevalence of endoscopically confirmed gastric ulcers after 12 weeks of NSAIDs and PPI cotherapy is 12.8% to 19.1%.[@b20-gnl-8-371] In case of misoprostol, the gastric ulcer prevalence due to NSAIDs has been found to be 8.1% to 10.5%.[@b17-gnl-8-371] When a group of patients at high risk for gastrointestinal complications received NSAIDs for 12 weeks in the current study, the occurrence rate of gastric ulcer in the rebamipide group was 11.1% in the PP analysis set, which did not differ from previously reported occurrence rate of gastric ulcer for PPIs. This result suggests that rebamipide is able to prevent gastric ulcer complications with an efficacy that is similar to that of PPIs when it is administered for 12 weeks to patents at high risk for NSAIDs complications. Furthermore, the use of rebamipide could be a cost-effective method of preventing NSAID-induced gastrointestinal complications in Korea.

Even when we regarded the withdrawal due to gastrointestinal injuries (the major AE for misoprostol) as a treatment failure, the therapeutic failure rates in the misoprostol and the rebamipide groups (13.1% and 13.6%, respectively) were not significantly different. However, the severity of gastrointestinal symptoms in the rebamipide group was significantly lower during the 12 weeks of NSAIDs administration. Therefore, rebamipide can effectively improve the gastrointestinal symptoms that occur with NSAIDs use. Because misoprostol decreases medication compliance due to gastrointestinal symptoms from the drug itself, rebamipide is thought to be a more appropriate medication for preventing NSAIDs complications. The rebamipide group also had significantly lower antacid consumption. Thus, the clinical usefulness of rebamipide is thought to be superior to that of misoprostol for patients who take NSAIDs for extended periods.

According to the safety analysis, nausea was more common in the misoprostol group compared with the rebamipide group. Although ADRs during the NSAIDs cotherapy occurred less frequently in the rebamipide group compared with the misoprostol group, the difference between the two groups was not significant. This result was confirmed in the Cochrane Database of Systematic Reviews and in the existing literature.[@b20-gnl-8-371],[@b21-gnl-8-371] The Cochrane Database of Systematic Reviews has reported that misoprostol increases the dropout risk due to AEs (especially nausea, diarrhea, and abdominal pain) by 1.6-fold.[@b20-gnl-8-371] Moreover, in a 6-month study of the prevention of serious NSAID-induced gastrointestinal complications, the early dropout rate due to AEs was found to be higher in the misoprostol group (27.4%, 1,210/4,404 subjects) than the placebo group (20.1%, 896/4,439 subjects) (p\<0.001).[@b21-gnl-8-371] Consequently, rebamipide can be safely used in clinical practice, even when administered with NSAIDs for 12 weeks.

For patients who require continuous administration of NSAIDs, the ability of rebamipide to reduce gastric ulcers and gastrointestinal symptoms has been recognized, and the results are similar to the previously reported effects of PPIs. In particular, misoprostol (a comparator drug) was associated with a high dropout rate due to gastrointestinal side effects, whereas the rebamipide group was proven to not be inferior to the misoprostol group in the ITT analysis, in which withdrew cases were regarded as treatment failures. The misoprostol group had a more rapid onset of AEs and more high-severity AEs. To a certain extent, these results are believed to be responsible for the high dropout rate and the low compliance in the misoprostol group, whereas rebamipide was determined to have high clinical safety and efficacy for patients who use NSAIDs for extended periods.

In conclusion, cotherapy with the mucosal protective agent rebamipide can safely and effectively prevent gastric ulcers in high-risk patients who require long-term NSAID administration.
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###### 

Nonsteroidal Anti-Inflammatory Drugs That Were Prescribed in the PRESENT Study (Intention to Treat Population)

  Prescribed NSAIDs      Misoprostol (n=237)   Rebamipide (n=242)   Total (n=479)   p-value[\*](#tfn3-gnl-8-371){ref-type="table-fn"}
  ---------------------- --------------------- -------------------- --------------- ---------------------------------------------------
  Aceclofenac (100 mg)   75 (31.7)             60 (24.8)            135 (28.2)      0.2489
  Meloxicam (7.5 mg)     117 (49.4)            132 (54.6)           249 (52.0)      
  Nabumetone (500 mg)    45 (19.0)             50 (20.7)            95 (19.8)       

Data are presented as number (%).

NSAID, nonsteroidal anti-inflammatory drug.

Chi-square test.

###### 

Withdrawal Rates in the PRESENT Study (Intention to Treat Population)

  Reason for dropping out                                       Misoprostol (n=237)   Rebamipide (n=242)   Total (n=479)   p-value[\*](#tfn5-gnl-8-371){ref-type="table-fn"}
  ------------------------------------------------------------- --------------------- -------------------- --------------- ---------------------------------------------------
  AEs                                                           10                    4                    14              
  Poor compliance with the protocol                             1                     3                    4               
  Consent withdrawal[†](#tfn6-gnl-8-371){ref-type="table-fn"}   33                    15                   48              
  Other                                                         0                     3                    3               
  Total, no. (%)                                                44 (18.6)             25 (10.3)            69 (14.4)       0.0103

AE, adverse event.

Chi-squared test;

Intractable gastrointestinal symptoms and insufficient pain control.

###### 

Demographic Characteristics of the Study Patients

  Characteristic                                        Misoprostol (n=237)   Rebamipide (n=242)                                     Total (n=479)   p-value
  ----------------------------------------------------- --------------------- ------------------------------------------------------ --------------- --------------------------------------------------
  Age, yr                                               55.8±12.2             55.8±12.2                                              55.8±12.2       0.9640[\*](#tfn8-gnl-8-371){ref-type="table-fn"}
  Sex                                                                                                                                                
   Male                                                 44 (18.6)             42 (17.4)                                              86 (18.0)       0.8119[†](#tfn9-gnl-8-371){ref-type="table-fn"}
   Female                                               193 (81.4)            200 (82.6)                                             393 (82.1)      
  Smokers[‡](#tfn10-gnl-8-371){ref-type="table-fn"}     36 (15.2)             42 (17.4)                                              78 (16.3)       0.5383[†](#tfn9-gnl-8-371){ref-type="table-fn"}
  Risk factors                                                                                                                                       
   Peptic ulcer history                                 27 (11.4)             21 (8.7)                                               48 (10.0)       0.3627[†](#tfn9-gnl-8-371){ref-type="table-fn"}
   ≥60 Years of age                                     124 (52.3)            118 (48.8)                                             242 (50.5)      0.4652[†](#tfn9-gnl-8-371){ref-type="table-fn"}
   Concomitant use of systemic corticosteroids          132 (55.7)            153 (63.2)                                             285 (59.5)      0.0951[†](#tfn9-gnl-8-371){ref-type="table-fn"}
  Concomitant disease                                                                                                                                
   Rheumatoid arthritis                                 149 (62.9)            160 (66.1)                                             309 (64.5)      0.5040[†](#tfn9-gnl-8-371){ref-type="table-fn"}
   Osteoarthritis                                       79 (33.3)             79 (32.6)                                              158 (33.0)      0.9226[†](#tfn9-gnl-8-371){ref-type="table-fn"}
   Ankylosing spondylitis                               14 (5.9)              5 (2.1)                                                19 (4.0)        0.0358[†](#tfn9-gnl-8-371){ref-type="table-fn"}
   Other[§](#tfn11-gnl-8-371){ref-type="table-fn"}      43 (18.1)             40 (16.5)                                              83 (17.3)       0.7174[†](#tfn9-gnl-8-371){ref-type="table-fn"}
  Modified Lanza score (from the screening endoscopy)                                                                                                
   Grade 0                                              124 (52.3)            132 (54.6)                                             256 (53.4)      0.1636[†](#tfn9-gnl-8-371){ref-type="table-fn"}
   Grade 1                                              48 (20.3)             55 (22.7)                                              103 (21.5)      
   Grade 2                                              40 (16.9)             24 (9.9)                                               64 (13.4)       
   Grade 3                                              25 (10.6)             30 (12.4)                                              55 (11.5)       
   Grade 4                                              0                     0                                                      0               
   Grade 5                                              0                     1 (0.4)[\|\|](#tfn12-gnl-8-371){ref-type="table-fn"}   1 (0.2)         

Data are presented as mean±SD or number (%).

Two-sample t-test;

Fisher exact test;

Smokers were defined as individuals who reported any tobacco use;

Osteoporosis, systemic lupus erythematous, and spinal stenosis;

Major deviation from the inclusion criteria.

###### 

Occurrence Rate of Gastric Ulcer at 12 Weeks

  Population                                      Ulcer prevalence   p-value[\*](#tfn15-gnl-8-371){ref-type="table-fn"}   95% two-sided CI   
  ----------------------------------------------- ------------------ ---------------------------------------------------- ------------------ -------------
  ITT[†](#tfn16-gnl-8-371){ref-type="table-fn"}   52 (21.9)          49 (20.3)                                            0.6497             −9.00--5.61

Data are presented as number (%).

CI, confidence interval; ITT, intention to treat.

Chi-squared test;

Missing endoscopy results at 12 weeks were considered to be ulcers.

###### 

Therapeutic Failure Rates in the Misoprostol and Rebamipide Groups

                                                                  Misoprostol (n=237)   Rebamipide (n=242)   p-value[\*](#tfn18-gnl-8-371){ref-type="table-fn"}
  --------------------------------------------------------------- --------------------- -------------------- ----------------------------------------------------
  Therapeutic failure[†](#tfn19-gnl-8-371){ref-type="table-fn"}   31 (13.1)             33 (13.6)            0.8580

Data are presented as number (%).

Chi-squared test;

Therapeutic failures include gastric ulcers and patients dropping out because of intractable gastrointestinal symptoms.

###### 

Gastrointestinal Symptom Severity in the Misoprostol and Rebamipide Groups

  Gastrointestinal symptoms   Visit      Misoprostol   Rebamipide   p-value[\*](#tfn21-gnl-8-371){ref-type="table-fn"}               
  --------------------------- ---------- ------------- ------------ ---------------------------------------------------- ----------- --------
  ITT (LOCF)                  Baseline   237           0.33±0.59    242                                                  0.24±0.54   0.0002
                              4 wk       218           0.80±1.14    236                                                  0.44±0.92   
                              8 wk       218           0.67±1.19    236                                                  0.36±0.78   
                              12 wk      218           0.67±1.24    236                                                  0.44±1.05   

ITT, intention to treat; LOCF, last observation carried forward.

Repeated-measures analysis of variance.

###### 

Number of Subjects Who Consumed Antacid during the 12 Weeks of Nonsteroidal Anti-Inflammatory Drug Administration

                                                                                                    Misoprostol   Rebamipide   Total        p-value
  ------------------------------------------------------------------------------------------------- ------------- ------------ ------------ ---------------------------------------------------
  The no. of subjects in the ITT population                                                         237           242          479          
  Antacid consumption                                                                               114 (48.1)    96 (39.7)    210 (43.8)   0.0630[\*](#tfn24-gnl-8-371){ref-type="table-fn"}
  The total no. of antacid tablets consumed per subject[†](#tfn25-gnl-8-371){ref-type="table-fn"}   11.18±22.79   7.19±15.49   9.16±19.53   0.0258[‡](#tfn26-gnl-8-371){ref-type="table-fn"}

Data are presented as number (%) or mean±SD.

ITT, intention to treat.

Chi-squared test;

Subjects who did not take antacids were regarded as having taken 0 tablets;

Two-sample t-test.

###### 

Treatment Emergent Adverse Events and Adverse Events in the Rebamipide and Misoprostol Groups

                                                       TEAEs                AEs[\*](#tfn29-gnl-8-371){ref-type="table-fn"}                                                                  
  ---------------------------------------------------- -------------------- ------------------------------------------------ -------------------- -------------------- -------------------- --------------------
  Total no., subjects (%) \[events\]                   161 (68.2) \[373\]   158 (65.3) \[347\]                               319 (66.7) \[720\]   166 (70.3) \[400\]   165 (68.2) \[405\]   331 (69.3) \[805\]
   Exact 95% CI                                        61.9--74.1           58.9--71.3                                       62.3--70.9           64.1--76.1           61.9--74.0           64.9--73.4
   p-value[†](#tfn30-gnl-8-371){ref-type="table-fn"}                                                                         0.4988                                                         0.6215
  No. of AEs                                                                                                                                                                                
   Mild                                                284 (76.1)           295 (85.0)                                       579 (80.4)           307 (76.8)           347 (85.7)           654 (81.2)
   Moderate                                            74 (19.8)            45 (13.0)                                        119 (16.5)           78 (19.5)            48 (11.9)            126 (15.7)
   Severe                                              15 (4.0)             7 (2.0)                                          22 (3.1)             15 (3.8)             10 (2.5)             25 (3.1)
  Serious AEs, subjects (%) \[events\]                 3 (1.3) \[3\]        7 (2.9) \[9\]                                    10 (2.1) \[12\]      3 (1.3) \[3\]        10 (4.1) \[13\]      13 (2.7) \[16\]
   Exact 95% CI                                        0.3--3.7             1.2--5.9                                         1.0--3.8             0.3--3.7             2.0--7.5             1.5--4.6
   p-value[†](#tfn30-gnl-8-371){ref-type="table-fn"}                                                                         0.3389                                                         0.0882

Data are presented as number (%).

TEAE, treatment emergent adverse event; AE, adverse event; CI, confidence interval.

All of the AEs (including the TEAEs) during the study;

Fisher exact test.

###### 

Major Treatment Emergent Adverse Events Related to the Study Drug of Subjects in Either Treatment Group by System Organ Class and Preferred Term

                               Misoprostol (n=236)   Rebamipide (n=242)   Total (n=478)        p-value[\*](#tfn33-gnl-8-371){ref-type="table-fn"}
  ---------------------------- --------------------- -------------------- -------------------- ----------------------------------------------------
  Total no. of TEAEs           69 (29.2) \[126\]     53 (21.9) \[95\]     122 (25.5) \[221\]   0.0746
  Gastrointestinal disorders                                                                   
   Upper abdominal pain        42 (17.8) \[56\]      38 (15.7) \[45\]     80 (16.7) \[101\]    0.5432
   Abdominal distension        12 (5.1) \[12\]       8 (3.3) \[9\]        20 (4.2) \[21\]      0.3680
   Nausea                      15 (6.4) \[19\]       4 (1.7) \[4\]        19 (4.0) \[23\]      0.0095
   Diarrhea                    10 (4.2) \[11\]       5 (2.1) \[10\]       15 (3.1) \[21\]      0.1980

Data are presented as subjects (%) \[events\].

TEAE, treatment emergent adverse event.

Fisher exact test.

[^1]: Current affiliation: Division of Gastroenterology, Department of Internal Medicine, Myongji Hospital, Seoul, Korea
